» Articles » PMID: 15680716

Impact of Mitral Valve Annuloplasty on Mortality Risk in Patients with Mitral Regurgitation and Left Ventricular Systolic Dysfunction

Overview
Date 2005 Feb 1
PMID 15680716
Citations 135
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: This study was designed to assess effects of mitral valve annuloplasty (MVA) on mortality in patients with mitral regurgitation (MR) and left ventricular (LV) systolic dysfunction.

Background: Mitral valve annuloplasty improves hemodynamics and symptoms in these patients, but effects on long-term mortality are not well established.

Methods: We retrospectively analyzed consecutive patients with significant MR and LV systolic dysfunction on echocardiography between 1995 and 2002. Cox regression analysis, including MVA as a time-dependent covariate and propensity scoring to adjust for differing probabilities of undergoing MVA, was used to identify predictors of death, LV assist device implantation, or United Network for Organ Sharing-1 heart transplantation.

Results: Of 682 patients identified, 419 were deemed surgical candidates; 126 underwent MVA. Propensity score derivation identified age, ejection fraction, and LV dimension to be associated with undergoing MVA. End points were reached in 120 (41%) non-MVA and 62 (49%) MVA patients. Increased risk of end point was associated with coronary artery disease (hazard ratio [HR] 1.80, 95% confidence interval [CI] 1.30 to 2.49), blood urea nitrogen (HR 1.01, 95% CI 1.005 to 1.02), cancer (HR 2.77, 95% CI 1.45 to 5.30), and digoxin (HR 1.66, 95% CI 1.15 to 2.39). Reduced risk was associated with angiotensin-converting enzyme inhibitors (HR 0.65, 95% CI 0.44 to 0.95), beta-blockers (HR 0.59, 95% CI 0.42 to 0.83), mean arterial pressure (HR 0.98, 95% CI 0.97 to 0.99), and serum sodium (HR 0.93, 95% CI 0.90 to 0.96). Mitral valve annuloplasty did not predict clinical outcome.

Conclusions: In this analysis, there is no clearly demonstrable mortality benefit conferred by MVA for significant MR with severe LV dysfunction. A prospective randomized control trial is warranted for further study of mortality with MVA in this population.

Citing Articles

Prognostic Implications of Guideline-Directed Medical Therapy for Heart Failure in Functional Mitral Regurgitation: A Systematic Review and Meta-Analysis.

Anastasiou V, Papazoglou A, Daios S, Moysidis D, Tsiartas E, Didagelos M Diagnostics (Basel). 2025; 15(5).

PMID: 40075845 PMC: 11898837. DOI: 10.3390/diagnostics15050598.


The Association Between Mitral Regurgitation and Long-Term Outcomes in Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: A Retrospective Large Sample Cohort Study.

Yan N, Wu P, Zhu B, Ma A, Wang X, Hai X Int J Gen Med. 2025; 18:703-715.

PMID: 39959459 PMC: 11829599. DOI: 10.2147/IJGM.S509816.


Study protocol for an international registry observational study evaluating clinical outcomes of transcatheter versus standard surgical mitral valve operation for secondary mitral regurgitation: the TEERMISO study.

Nappi F, Avtaar Singh S, Salsano A, Spadaccio C, Shingu Y, Wakasa S BMJ Open. 2025; 15(1):e086888.

PMID: 39779262 PMC: 11749030. DOI: 10.1136/bmjopen-2024-086888.


A Protocol Investigation Comparing Transcatheter Repair with the Standard Surgical Procedure for Secondary Mitral Regurgitation.

Nappi F, Avtaar Singh S, Salsano A, Nassif A, Shingu Y, Wakasa S J Clin Med. 2025; 13(24.

PMID: 39768667 PMC: 11677399. DOI: 10.3390/jcm13247742.


Secondary mitral regurgitation surgical management: a narrative review.

Eapen S, Zaky M, Kostibas M, Robich M Cardiovasc Diagn Ther. 2024; 14(5):958-973.

PMID: 39513148 PMC: 11538845. DOI: 10.21037/cdt-24-6.